Fundz

Who to call at Amylyx Pharmaceuticals, and when

Fundz watches for the moments Amylyx Pharmaceuticals starts buying, and tells you who to reach.

  • An alert the day Amylyx Pharmaceuticals raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Amylyx Pharmaceuticals, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Amylyx Pharmaceuticals Announces Development Candidate AMX0318 in Collaboration with Gubra

Jan 08, 2026

Contract Type

collaboration

CambridgeBiotechnologyHealthcareHealth CareTherapeuticsPharmaceutical

Description

On January 8, 2026, Amylyx Pharmaceuticals announced the selection of AMX0318 as a development candidate for post-bariatric hypoglycemia and other rare diseases. This was achieved through a research collaboration with Gubra A/S, a company specializing in peptide-based drug discovery. Gubra will receive over $50 million in success-based milestones and royalties, along with an immediate milestone payment of $4 million.

Company Information

Company

Amylyx Pharmaceuticals

Location

Cambridge, Massachusetts, United States

About

Amylyx Pharmaceuticals, Inc. is committed to supporting and creating more moments for the neurodegenerative disease community through the discovery and development of innovative new treatments. Amylyx is headquartered in Cambridge, Massachusetts and has operations in Canada and EMEA. For more information, visit amylyx.com and follow us on LinkedIn and Twitter. For investors, please visit investors.amylyx.com.

Related People

Camille
Likely contact at this company
••••••••@••••••••

See Camille's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Amylyx Pharmaceuticals's next move

Learn about Strategic plan

Amylyx Pharmaceuticals signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.